Machine learning-based prognostic prediction for cutaneous malignant melanoma patient survival [0.03%]
基于机器学习的黑色素瘤患者生存预测模型
Yuxin Wang,Jiajia Liu,Huawei Wu et al.
Yuxin Wang et al.
Background: Cutaneous malignant melanoma (CMM) is a highly malignant tumor that necessitates early diagnosis and precise survival prediction. The development of accurate prognostic models is essential for improving patien...
Harnessing the power of artificial intelligence for clinical trials in cancer [0.03%]
利用人工智能的力量进行癌症临床试验
Gamze Sonmez,Yigit Yazarkan,Taha Koray Sahin et al.
Gamze Sonmez et al.
Introduction: Cancer research has become increasingly data-intensive, with digital pathology, imaging, and genomic sequencing generating vast, heterogeneous datasets. Artificial intelligence (AI) now plays a growing role ...
Learning from late-stage trial failures in higher-risk myelodysplastic syndromes: towards adaptive and biomarker-enriched designs [0.03%]
高危骨髓增生异常综合征晚期临床试验失败的教训：走向适应性和生物标志物富集设计
Amer M Zeidan,Sofia Aakko,Maximilian Stahl et al.
Amer M Zeidan et al.
Introduction: Higher-risk myelodysplastic syndromes (HR-MDS) remain an area of high unmet need in which multiple randomized late-stage trials have failed to improve outcomes beyond hypomethylating agent monotherapy, despi...
The role of PSMA PET/CT imaging in identifying low-risk prostate cancer candidates for active surveillance after biopsy [0.03%]
PSMA PET/CT影像在活检后识别低危前列腺癌的积极监测候选者中的作用
Levent Kabasakal,Gürsan Kaya
Levent Kabasakal
The pricing barrier: cost-effectiveness of Glofitamab for relapsed/refractory DLBCL in China beyond threshold and value-based pricing strategy considerations [0.03%]
葛利西妥滨治疗复发/难治DLBCL的经济性分析及其在中国的高值药品医保准入策略探索
Shen Lin,Xiangzhen Wang,Lijing Yang et al.
Shen Lin et al.
Background: To assess the cost-effectiveness of Glofitamab plus Gemcitabine and Oxaliplatin (Glofit-GemOx) versus Rituximab plus Gemcitabine and Oxaliplatin for treating relapsed/refractory diffuse large B-cell lymphoma (...
The clinical utility of molecular residual disease testing in early-stage breast cancer [0.03%]
早期乳腺癌分子残留疾病检测的临床应用价值
John P Micha,Randy Bohart,Bram H Goldstein
John P Micha
Introduction: Breast cancer is the most commonly-diagnosed malignancy among women. Currently, radiologic imaging is indicated for defined surveillance periods and to assess or corroborate patient symptomatology. More rece...
Immune checkpoint inhibitors in urothelial carcinoma: a practical framework for patient selection, toxicity management, response assessment, and treatment sequencing [0.03%]
免疫检查点抑制剂在尿路上皮癌治疗中的应用：患者选择、毒性管理、疗效评估及治疗顺序的实用框架
Abdul Rahman Al Armashi,Jenny Gong,Pedro Barata et al.
Abdul Rahman Al Armashi et al.
Introduction: Managing urothelial carcinoma with immune checkpoint inhibitors requires addressing issues beyond clinical outcomes. Implementation difficulties affect most patients, predictive biomarkers show limited utili...
Integrating liquid biopsies in non-small cell lung cancer diagnosis and management: opportunities and challenges [0.03%]
液体活检在非小细胞肺癌诊断和管理中的应用：机遇与挑战
Jeong Uk Lim,Yuko Oya,Rui Fu et al.
Jeong Uk Lim et al.
Introduction: Liquid biopsy has emerged as an important approach to capture tumor-derived material from blood and other body fluids, offering a minimally invasive window into cancer biology. In non - small cell lung cance...
The evolving survival landscape in advanced non-small cell lung cancer: an interrupted time series analysis [0.03%]
晚期非小细胞肺癌的生存现状演变：一项中断时间序列分析
Jianwei Ji,Taoying Li,Zhanwu Li et al.
Jianwei Ji et al.
Background: Treatment for advanced non-small cell lung cancer (NSCLC) has shifted from chemotherapy to targeted therapy and immunotherapy. We aimed to evaluate the effects of these novel therapies on advanced NSCLC in rea...
The role of zongertinib, a highly selective tyrosine kinase inhibitor, in targeting HER2-mutant NSCLC: a bench-to-bedside review [0.03%]
新型赫赛汀耐药乳腺癌的治疗策略及HER2突变型非小细胞肺癌的靶向治疗研究进展：从实验室到临床
John V Heymach,Sanjay Popat,Egbert F Smit et al.
John V Heymach et al.
Introduction: HER2 is mutated in 2-4% of non-small cell lung cancers (NSCLC) and is associated with poor prognosis. Tyrosine kinase inhibitors (TKIs) targeting HER2 have historically been hampered by insufficient efficacy...